Alpha-9 Oncology
Greet Heremans is an experienced clinical operations leader with a strong background in oncology and a history of advancing clinical trials. Currently serving as Vice President of Clinical Operations at Alpha-9 Oncology, Greet previously held the role of Vice President, Clinical Operations at Sutro Biopharma, Inc., leading a significant organizational transition into global registrational trials. Greet's career at Genentech included strategic leadership of the Cross-Therapeutic Biomarker Operations department and oversight of a substantial oncology trial portfolio. Earlier roles at Roche Pharmaceuticals and IQVIA encompassed project management and operational leadership within clinical studies. Greet holds an Executive Master of Business Administration from the University of San Francisco and multiple degrees in Pharmacy from the University of Antwerp.
This person is not in any teams
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.